Table 1.
Summary of discussed metalloproteinase inhibitors in cancer-related clinical trials.
| Name | Target | Tumor entity | Identifier |
|---|---|---|---|
| Marimastat (BB-2516) |
Broad spectrum | SCLC | NCT00003011 |
| NSCLC | NCT00002911 | ||
| Breast cancer | NCT00003010 | ||
| Prinomastat (AG3340) |
MMP-2/-3/-9/-13 | NSCLC | NCT00004199 |
| Brain and Central Nervous System Tumors plus RT | NCT00004200 | ||
| Prostate cancer | NCT00003343 | ||
| Neovastat (AE-941) | MMP-2/-9/-12 | NSCLC plus RT | NCT00005838 |
| Multiple Myeloma | NCT00022282 | ||
| Kidney cancer | NCT00005995 | ||
| Metastat (Col-3, Incyclinide) |
MMP-2, MMP-9 | AIDS-Related Kaposi’s Sarcoma | NCT00020683 |
| Advanced Solid Malignancies | NCT00003721 | ||
| Refractory metastatic cancer | NCT00001683 | ||
| Brain and Central Nervous System Tumors | NCT00004147 | ||
| INCB7839 (Aderbasib) | ADAM10, ADAM17 | Gliomas | NCT04295759 |
| Diffuse Large B Cell Non-Hodgkin Lymphoma | NCT02141451 | ||
| HER2+ metastatic Breast Cancer | NCT01254136 | ||
| NCT00864175 | |||
| Solid Tumors | NCT00820560 | ||
| Andecaliximab (GS-5745) |
MMP-9 | Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02864381 |
| NCT02545504 | |||
| NCT02862535 | |||
| Advanced solid tumors | NCT01803282 | ||
| Glioblastoma | NCT03631836 |